Veru Q3 net loss $22.2M on 46% revenue decline; sabizabulin EUA under FDA, UK, EMA review

VERU INC.

2022-Q3 EPS reported -$0.53 revenue$36,765,721

Net loss of $22.2M ($0.28 per share) vs $2.7M loss a year ago; revenue $9.6M vs $17.7M.
Sabizabulin EUA submitted to FDA June 2022; UK MHRA granted expedited review; EMA Emergency Task Force reviewing for EU emergency use.
Phase 3 COVID-19 trial showed 55.2% relative reduction in deaths; results published in NEJM Evidence.
ENTADFI (tadalafil/finasteride) commercially launched for BPH; FC2 prescription sales down 50% due to telemedicine customer issues.
Cash and equivalents $100.6M as of June 30, 2022, down from $122.4M at Sep 30, 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.